Vascular protection data presented at the European Society of Cardiology's (ESC) 2007 Annual Congress in Vienna have shown that Daiichi-Sankyo's angiotensin-receptor blocker (ARB), olmesartan, can prevent and reverse atherosclerotic processes including: oxidative stress,1 endothelial inflammation,2 remodelling of cardiac vascular tissues,3,4 development of atherosclerotic lesions5 and reduction of large plaques.6,7 These additional vascular protective effects appear to be independent of olmesartan's blood-pressure-reducing function.6,7.
